IP Library › Granted Patent US 9,603,851
Granted Patent B2
US 9,603,851 · App. 14/873,579 · Granted Mar 28, 2017

Combination therapy

Inventors: Thomas Klein (Radolfzell, DE); Rolf Grempler (Birkenhard/Warthausen, DE); Michael Mark (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH
A61K31/522A61K31/00A61K38/2278A61K38/26A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,851
App. No.
14/873,579
Granted
Mar 28, 2017
Kind
B2
Abstract

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.

Claims (2)

1. A method for treating or reducing the risk of skin necrosis associated or induced by (a) injections by a needle or syringe pierced through the skin or (b) infusions, in a patient in need thereof, said method comprising orally administering linagliptin to said patient.

2. The method according to claim 1 , wherein the skin necrosis is from subcutaneous injection of a GLP-1 receptor agonist, insulin, or insulin analog.

Priority Claims (2)
EP 10162036 · May 5, 2010 · regional
EP 11155154 · Feb 21, 2011 · regional
Continuity (2)
Continuation 13695492
Related Publication 20160038500A1 · Feb 11, 2016